The study evaluated more than 1,700 Alzheimer’s cases and more than 1,700 age-matched controls. Results demonstrated that single nucleotide polymorphisms (SNPs) in a gene that is homologous to the RPS3A gene were associated with Alzheimer’s and implicate this gene, adjacent genes, or other functional variants in the development and progression of this disease.
In the past year, Celera Diagnostics’ scientists have also identified novel genetic variants in the glyceraldehyde-3-phosphate dehydrogenase (GAPD) gene associated with Alzheimer’s, and also in the amyloid precursor protein binding protein B2 (APPB2).
“These findings, coupled with those published last year around GAPD and the APPB2 gene, provide valuable insight into the etiology of Alzheimer’s and hold significant promise of enabling the development of new diagnostics and targeted therapeutics,” said Dr Thomas White, chief scientific officer at Celera Diagnostics.